NCT00116545View on ClinicalTrials.gov

TART - Troglitazone Atherosclerosis Regression Trial

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

288

Participants

Timeline

Start Date

January 31, 1997

Primary Completion Date

April 30, 2000

Study Completion Date

April 30, 2000

Conditions
AtherosclerosisDiabetes Mellitus
Interventions
DRUG

troglitazone

Trial Locations (1)

90033

Atherosclerosis Research Unit, Division of Cardiovascular Medicine, Department of Medicine, Los Angeles

All Listed Sponsors
lead

Parke-Davis

INDUSTRY

NCT00116545 - TART - Troglitazone Atherosclerosis Regression Trial | Biotech Hunter | Biotech Hunter